NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
20/01/2026
Voltar para busca
Dado oficial do USPTO
LYBALVI
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
LYBALVI
ST13
US500000090765835Classe
35, 36, 44, 45
Pedido
90765835
Registro
8111270
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
20/01/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
35, 36, 44, 45
Data de depósito
10/06/2021
Data de registro
20/01/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/01/2026
Última transação
20/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
21/01/2022
Primeiro uso no comércio
23/02/2022
Código do desenho
4
Tipo de titular
03
Localização do titular
Dublin 4, IE
Examinador
MITTLER, KEVIN A
Unidade examinadora
T10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Alkermes Pharma Ireland Limited
Representantes
Norm J. Rich FOLEY & LARDNER LLP
Classificação técnica
Classes Nice
Classe 35Classe 36Classe 44Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Logistics management in the field of medicationbusiness services in the nature of supporting the coordination of medication delivery to avoid product delivery delays; providing business administration information to patients and health care providers about medication reimbursement options regarding reimbursement procedures; providing information about pharmaceutical servicesproviding information about pharmacy authorization in the nature of prescription fulfillment and approval instructions for delivery of medication in the nature of accepting payment terms
Classe 36
Providing information about pharmaceutical coverage by patient health plans; providing insurance administration information to patients and health care providers about medication reimbursement options; insurance services being support services for patients and for health care providers on behalf of their patientsproviding health benefit verification services to determine coverage of medication treatment; financial administration of medication reimbursement programs being support services for patients and for health care providers on behalf of their patientscoordinating medication reimbursement programs
Classe 44
Providing educational information in the field of medication treatment to health care providers and patients; providing educational information about the diagnosticprophylactictherapeutic properties of pharmaceuticals and pharmaceutical products for medical purposes
Classe 45
Support services for health care providers and their patients in the nature of providing case management servicescoordinating the procurement of medication in the nature of conducting benefits verification with payers to facilitate prescription fulfilment and coordinating with non-commercial pharmacy to facilitate prescription fulfilment for patients eligible for patient assistance program; providing case management services in the nature of support services for patients and for health care providers on behalf of their patientscoordinating the procurement of medication in the nature of conducting benefits verification with payers to facilitate prescription fulfilment and coordinating with non-commercial pharmacy to facilitate prescription fulfilment for patients eligible for patient assistance program
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
20/01/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
30/12/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
30/12/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
27/05/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
26/05/2023
EX1G
SOU EXTENSION 1 GRANTED
26/05/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
25/05/2023
EXT1
SOU EXTENSION 1 FILED
19/05/2023
IUAF
USE AMENDMENT FILED
19/05/2023
EEXT
SOU TEAS EXTENSION RECEIVED
19/05/2023
EISU
TEAS STATEMENT OF USE RECEIVED
19/05/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
29/11/2022
NEWN
NEW NOA TO ISSUE
17/10/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
28/07/2022
IUCN
NOTICE OF ALLOWANCE CANCELLED
26/07/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
31/05/2022
PUBO
PUBLISHED FOR OPPOSITION
31/05/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/05/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/04/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
26/04/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
26/04/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
26/04/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
26/04/2022
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
15/04/2022
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
29/03/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/03/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
14/03/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/03/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
14/03/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/03/2022
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
11/03/2022
PBMR
WITHDRAWN FROM PUB - MANAGING ATTORNEY REQUEST
11/03/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/03/2022
DOCK
ASSIGNED TO EXAMINER
01/03/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
30/08/2021
NWAP
NEW APPLICATION ENTERED
14/06/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LYBALVI ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.